Preclinical development and clinical studies of targeted JAK/STAT combined Anti-PD-1/PD-L1 therapy

被引:4
作者
Chen, Miaomiao [1 ]
Wang, Siliang [1 ,2 ]
机构
[1] China Med Univ, Dept Oncol, Shengjing Hosp, Shenyang 110004, Peoples R China
[2] 36 Sanhao Rd, Shenyang 110004, Peoples R China
关键词
PD-1/PD-L1; JAK/STAT signalling pathway; Drug combinations; Immunotherapy resistance; TUMOR-ASSOCIATED MACROPHAGES; REGULATORY T-CELLS; JAK-STAT PATHWAY; PD-1; BLOCKADE; INTERFERON-GAMMA; CANCER-CELLS; INHIBITION; EXPRESSION; RESISTANCE; CARCINOMA;
D O I
10.1016/j.intimp.2024.111717
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Programmed cell death protein 1 (PD -1) binds to its ligand to help tumours evade the immune system and promote tumour progression. Although anti-PD-1/PD-L1 therapies show powerful effects in some patients, most patients are unable to benefit from this treatment due to treatment resistance. Therefore, it is important to overcome tumour resistance to PD-1/PD-L1 blockade. There is substantial evidence suggesting that the JAK/ STAT signalling pathway plays a significant role in PD-1/PD-L1 expression and anti-PD-1/PD-L1 treatment. Herein, we describe the effects of the JAK/STAT signalling pathway on PD-1/PD-L1. Subsequently, the relationship between molecular mutations in the JAK/STAT signalling pathway and immune resistance was analysed. Finally, the latest advancements in drugs targeting the JAK/STAT pathway combined with PD1/PD-L1 inhibitors are summarised.
引用
收藏
页数:7
相关论文
共 50 条
[31]   Predictive Markers for the Efficacy of Anti-PD-1/PD-L1 Antibodies in Lung Cancer [J].
Shukuya, Takehito ;
Carbone, David P. .
JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (07) :976-988
[32]   Targeting Protein Kinases to Enhance the Response to anti-PD-1/PD-L1 Immunotherapy [J].
Garcia-Aranda, Marilina ;
Redondo, Maximino .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (09)
[33]   Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment [J].
Sato, Hiro ;
Okonogi, Noriyuki ;
Nakano, Takashi .
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2020, 25 (05) :801-809
[34]   Burgeoning Exploration of the Role of Natural Killer Cells in Anti-PD-1/PD-L1 Therapy [J].
Bai, Rilan ;
Cui, Jiuwei .
FRONTIERS IN IMMUNOLOGY, 2022, 13
[35]   Anti-PD-1/PD-L1 therapy for infectious diseases: learning from the cancer paradigm [J].
Rao, Martin ;
Valentini, Davide ;
Dodoo, Ernest ;
Zumla, Alimuddin ;
Maeurer, Markus .
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2017, 56 :221-228
[36]   Clinical benefit of neoadjuvant anti-PD-1/PD-L1 utilization among different tumors [J].
Li, Zhiyang ;
Wu, Xin ;
Zhao, Yanjie ;
Xiao, Yinan ;
Zhao, Yunuo ;
Zhang, Ting ;
Li, Hui ;
Sha, Fushen ;
Wang, Yating ;
Deng, Lei ;
Ma, Xuelei .
MEDCOMM, 2021, 2 (01) :60-68
[37]   The Role of Anti-PD-1/PD-L1 Agents in Melanoma: Progress to Date [J].
Tsai, Katy K. ;
Daud, Adil I. .
DRUGS, 2015, 75 (06) :563-575
[38]   In Vivo Syngeneic Tumor Models with Acquired Resistance to Anti-PD-1/PD-L1 Therapies [J].
Denis, Morgane ;
Grasselly, Chloe ;
Choffour, Pierre-Antoine ;
Wierinckx, Anne ;
Mathe, Doriane ;
Chettab, Kamel ;
Tourette, Anne ;
Talhi, Nolan ;
Bourguignon, Aurore ;
Birzele, Fabian ;
Kress, Elsa ;
Jordheim, Lars Petter ;
Klein, Christian ;
Matera, Eva-Laure ;
Dumontet, Charles .
CANCER IMMUNOLOGY RESEARCH, 2022, 10 (08) :1013-1027
[39]   Outcomes after progression of disease with anti-PD-1/PD-L1 therapy for patients with advanced melanoma [J].
Patrinely, James R., Jr. ;
Baker, Laura X. ;
Davis, Elizabeth J. ;
Song, Haocan ;
Ye, Fei ;
Johnson, Douglas B. .
CANCER, 2020, 126 (15) :3448-3455
[40]   Predictive and Prognostic Role of PD-L1 in Urothelial Carcinoma Patients with Anti-PD-1/PD-L1 Therapy: A Systematic Review and Meta-Analysis [J].
Liu, Haoran ;
Ye, Tao ;
Yang, Xiaoqi ;
Lv, Peng ;
Wu, Xiaoliang ;
Thou, Hui ;
Lu, Hongyan ;
Tang, Kun ;
Ye, Zhangqun .
DISEASE MARKERS, 2020, 2020